Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
et al., Viruses, doi:10.3390/v14040841 (Review)
Review of lethal mutagenesis for RNA viruses, as used by molnupiravir, favipiravir, and ribavirin. Authors note the potential for permanently modifying the genomes of patients while causing teratogenicity or embryotoxicity, and the potential of creating novel virus variants with increased pathogenicity and transmissibility.Authors recommend a registry of patients for long-term monitoring of potential adverse effects, including genetic, carcinogenic, teratogenic, and embryotoxic damage.
Hadj Hassine et al., 4/18/2022, peer-reviewed, 3 authors.
Contact:
lmenendez@cbm.csic.es (corresponding author), hadj_hassine_ekbell@yahoo.fr, benmhadhebmanel@yahoo.fr.
hadjhassine
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.